Short description
Healios develops treatments for retinal diseases and age-related macular degeneration (AMD) using cell technology.
Description
Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Tokyo, Tokyo, Japan, Asia
Founded on
February 24, 2011
Exited on
June 16, 2015
Went public on
June 16, 2015
Stock symbol
4593
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noway Youcantaccess, Blurry Noaccess, Uh Ohhhh, Blurry Noaccess, Absolutely Noaccess, Uh Ohhhh, Noaccessforu, Absolutely Noaccess, Uh Ohhhh, Absolutely Noaccess
Sign in for full access